No, aducanumab is not an Alzheimer’s drug either
Failure at a futility analysis blows a big hole in Biogen's pipeline. Can the company buy in growth or will its valuation sink enough for it to become a target?
Neurocrine voyages into gene therapy
A collaboration over four gene therapy programmes substantially beefs up Neurocrine’s pipeline, while Voyager Therapeutics gets a much-needed infusion of credibility.
Upcoming events – Crucial data for Neurocrine and Redhill
Neurocrine Biosciences is hoping to untick the box on its previous Tourette’s failures, while Redhill hopes that it has the Talicia keys.
Mid-cap investors see Eastern promise in the third quarter
Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…
US regulators on track for another strong year
If the US drugs regulator picks up the pace in the second half of the year, 2018 could be a bumper year for novel medicine approvals.
FDA’s flashing green light boosts novel drug approvals
No slowdown at the FDA, as regulator remains on track to approve at least 43 new drugs this year.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.